Summer 2026
Camera Image Processing Algorithm Intern
Posted on 1/23/2026
Intuitive Surgical
10,001+ employees
Manufactures robotic surgical systems and services
No salary listed
Sunnyvale, CA, USA
In Person
 AI & Machine Learning (1) |
|---|
Get referred to Intuitive Surgical
Find people who can refer or advise you
- Knowledgeable and significant hands-on experience in designing and implementing digital image and video signal processing algorithms.
- Good knowledge about color science, human perception and image quality metrics.
- Solid imaging-related physics knowledge and mathematical modeling foundation.
- Proficient in Matlab, Python and C/C++ algorithm prototyping.
- Good machine learning knowledge and hands-on experience applying deep learning-based methods to image or video processing problems
- University Enrollment: Must be currently enrolled in and returning to an accredited degree-seeking academic program after the internship.
- Internship Work Period: Must be available to work full-time (approximately 40 hours per week) during a 10-12 week period starting May or June. Specific start dates are shared during the recruiting process.
- Current enrollment in Computer Science, Computer Engineering, Electrical Engineering, Imaging Science or related degree-seeking program at the Master’s, or Doctorate level.
- Evaluate and benchmark existing imaging processing algorithms and pipeline performance. Identify root cause of IQ issues and solution space constraints.
- Design, implement and optimize new algorithms with vision pipeline simulator.
- Algorithm and pipeline calibration, IQ validation lab work and documentation.
- Obtain surgical feedback from clinical development team and iterate into algorithm designs and optimization.
- High dynamic range imaging knowledge and experience, especially tone-mapping algorithms.
- Experience with PyTorch (preferred) or similar deep learning frameworks for image enhancement or computer vision applications
- GPU programming experience with CUDA
- Familiar with CMOS image sensor, camera optics, and its signal processing pipeline.
Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.
Company Size
10,001+
Company Stage
IPO
Headquarters
Sunnyvale, California
Founded
1995
Get referred to Intuitive Surgical
Find people who can refer or advise you
Simplify's Take
What believers are saying
- da Vinci 5 CE mark in July 2025 enables faster Europe adoption across adult and pediatric procedures
- Over 100 May 2026 da Vinci 5 updates strengthen differentiation with telepresence digital ruler multi-arm targeting
- Ion procedures surged 39% in Q1 2026 showing strong early traction in endoluminal robotic surgery
What critics are saying
- Medtronic and J&J launch force-feedback cardiac robots targeting 160K US thoracoscopic cases in 12-18 months
- Class II da Vinci recall delays procedures and triggers reimbursement scrutiny at major US hospital systems in 3-9 months
- Tariffs on Asian instrument imports compress gross margins from 68-69% target within 6-12 months with 55-70% probability
What makes Intuitive Surgical unique
- da Vinci 5 leads with force feedback, 99% uptime, and 30+ years clinical workflow data
- 85% recurring revenue from 13000 installed systems creates resilient subscription-like income streams
- Ion endoluminal platform grew 36% in Q2 2026 expanding beyond da Vinci into new procedures
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Intuitive Surgical could emerge as a dark horse in the anti-obesity market as bariatric surgery proves more effective than GLP-1 drugs for long-term weight loss. A recent study of over 50,000 patients found surgery patients lost an average of 58 pounds after two years, compared to just 12 pounds for those using GLP-1 medications. The study also showed surgery delivers more sustainable results. Gastric bypass patients maintain around 52% of their excess weight loss after 10 years, whilst GLP-1 users often regain all lost weight after stopping treatment. Intuitive's da Vinci surgical system offers minimally invasive bariatric surgery options. The company generated $10.1 billion in revenue last year, up from $8.4 billion, with profit margins around 28%. Despite shares falling over 20% this year, the company's position in surgical innovation makes it a compelling long-term investment.
Intuitive Surgical has experienced recent share price weakness, declining 3% in one day with negative returns over the past week, month and three months. The stock currently trades at $452.66, down 10.1% over one month and 19.45% year-to-date, though three-year total shareholder returns remain strong at 77.19%. The medical technology company reports annual revenue of $10.1 billion and net income of $2.9 billion, maintaining a dominant position in minimally invasive surgical technology. According to one valuation analysis, Intuitive Surgical's fair value sits at $532.46, suggesting the stock is undervalued by approximately 15% at current levels. The analysis projects 12% annual revenue growth over the next five years, supported by recurring revenues from spare parts and software licences, with profit margins expected to reach 30% from the current 28.6%.
Intuitive Surgical shares rose 23% following Jim Cramer's recommendation on CNBC's Squawk on the Street in June 2025, where he urged investors to "just go buy ISRG". The medical robotics company experienced a 27% surge in October after reporting third-quarter earnings that beat analyst estimates. Revenue reached $2.51 billion against expectations of $2.40 billion, whilst adjusted earnings per share hit $2.40 versus the predicted $1.98. However, the stock declined 2.7% in January 2026 after Intuitive Surgical released preliminary fourth-quarter results, citing concerns that Medicaid funding cuts and competing products could slow growth of its robotic surgical systems. Despite the recent setback, shares remain up significantly since Cramer's initial endorsement, though they're down 7.8% over the past year.
Intuitive Surgical faces headwinds from tariffs and increased competition in the robotic-assisted surgery market, yet its fundamentals remain strong. The medical device company reported fourth-quarter revenue growth of 19% to $2.87 billion, whilst adjusted earnings per share rose 14.5% to $2.53. Procedures using its da Vinci surgical system increased 17%, with the installed base growing 12% to 11,106 units. However, the stock trades at 47.6 times forward earnings, compared to the healthcare sector average of 17.1. New competition is emerging, with Medtronic's Hugo system recently cleared and Johnson & Johnson expected to launch its own device soon. Despite these challenges, Intuitive Surgical maintains advantages through switching costs and extensive real-world data, whilst the underpenetrated robotic-assisted surgery market offers long-term growth potential.
Intuitive Surgical maintained a 37% operating margin in Q4 despite tariffs creating a 95 basis point drag, alongside higher facility costs and unfavourable product mix from newer platforms like da Vinci 5 and Ion. The company offset these pressures through product cost reductions, component savings and manufacturing efficiencies. Procedure growth of 18% in Q4 and recurring revenue now comprising 81% of total revenues provided operating leverage. Management's 2026 gross margin guidance of 67-68% suggests continued stability, even as tariff headwinds are expected to increase to roughly 1.2% of revenues. Meanwhile, Boston Scientific expanded adjusted operating margins by 100 basis points to 28% in 2025, though tariffs will offset favourable product mix in 2026. The company expects 50-75 basis points operating margin expansion in 2026 through scale efficiencies and supply-chain optimisation.